Abstracts tagged "Pediatric rheumatology"

Abstract Number: 023 • 2020 Pediatric Rheumatology Symposium
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Suzanne Li¹, Aashka Patel ², Elena Pope ³, Thomas Mason ⁴, Vidya Sivaraman ⁵, Fatma Dedeoglu ⁶, Kathryn Torok ⁷, Katie Stewart ⁸, Gloria Higgins ⁹, C. Egla Rabinovich ¹⁰, Robert Fuhlbrigge ¹¹, Maria Ibarra ¹², Sandy Hong ¹³, Polly Ferguson ¹⁴, Mara Becker ¹⁵, Brian Feldman ¹⁶ and Ronald Laxer ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Hackensack University Medical Center, Hackensack, ³Hospital For Sick Kids, Toronto, Canada, ⁴Rochester, ⁵Division of Rheumatology, Nationwide Children's Hospital, Bexley, ⁶Boston Children's Hospital, Boston, ⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁸UT Southwestern, Dallas, ⁹Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁰Duke University Hospital, Durham, ¹¹University of Colorado, Aurora, ¹²Children's Mercy Kansas City, Kansas City, ¹³University of Iowa Stead Family Children's Hospital, Iowa City, ¹⁴University of Iowa Carver College of Medicine, Iowa City, ¹⁵Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ¹⁶The Hospital for Sick Children, Toronto, Canada, ¹⁷The Hospital for Sick Children and University of Toronto, Toronto, Canada
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in…
Abstract Number: 072 • 2020 Pediatric Rheumatology Symposium
Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases
Camille Beaufils¹, Catherine Proulx ², Annaliesse Blincoe ³, Pierre Teira ⁴, Henrique Bittencourt ⁴, Sonia Cellot ⁵, Michel Duval ⁴, Johannes Roth ⁶, Marie-Paule Morin ⁷, Jean Jacques De Bruycker ⁷, Julie Couture ⁷, Kathryn Samaan ⁸, Helene Decaluwe ⁷, Fabien Touzot ⁷, Elie Haddad ⁷ and Julie Barsalou ⁷, ¹Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Quebec, Canada, ²Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada, ³Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Montreal, Canada, ⁴Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁵Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Canada, ⁶Division of Pediatric Rheumatology, Children Hospital of Eastern Ontario, Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada, ⁷Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁸Division of Pediatric Rheumatology-Immunology,-Allergy, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
Background/Purpose: Patients with refractory rheumatic diseases face poor quality of life, long-term sequelae and life-threatening complications. With advances in allogenic hematopoietic stem cell transplantation (allo-HSCT),…
Abstract Number: 024 • 2020 Pediatric Rheumatology Symposium
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq ², Mary Buckley ³, Kathryn Torok ⁴, Barbara Edelheit ⁵, Kaleo Ede ⁶ and C. Egla Rabinovich ⁷, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Montclair State University, montclair, ³Duke University, Durham, ⁴Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, ⁵CT Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, ⁷Duke University Hospital, Durham
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium
Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma
Suzanne Li¹, Mara Becker ², Sandy Hong ³, Polly Ferguson ⁴, Themba Nyrienda ⁵, Tracy Andrews ⁶, Katie Stewart ⁷, C. Egla Rabinovich ⁸, Robert Fuhlbrigge ⁹, Thomas Mason ¹⁰, Elena Pope ¹¹, Maria Ibarra ¹², Fatma Dedeoglu ¹³, Gloria Higgins ¹⁴, Ronald Laxer ¹⁵, Marilynn Punaro ¹⁶ and Kathryn Torok ¹⁷ for the CARRA investigators, ¹Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, ³University of Iowa Stead Family Children's Hospital, Iowa City, ⁴University of Iowa Carver College of Medicine, Iowa City, ⁵Hackensack Univesity Medical Center, Hackensack, ⁶Rutgers University, Newark, ⁷UT Southwestern, Dallas, ⁸Duke University Hospital, Durham, ⁹University of Colorado, Aurora, ¹⁰Rochester, ¹¹Hospital For Sick Kids, Toronto, Canada, ¹²Children's Mercy Kansas City, Kansas City, ¹³Boston Children's Hospital, Boston, ¹⁴Nationwide Childrens Hospital/ The Ohio State University, Columbus, ¹⁵The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁶Dallas, Texas, ¹⁷Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
Abstract Number: 027 • 2020 Pediatric Rheumatology Symposium
Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition
Sofia Torreggiani¹, Pascal Pillet ², Fabiano de Oliveira Poswar ³, Anna Kozlova ⁴, Anna Shcherbina ⁴, Marietta De Guzman ⁵, Jacob Mitchell ⁶, Gina A. Montealegre Sanchez ⁷, Katherine Townsend ⁸, Kim Johnson ⁹, Adriana Almeida de Jesus ¹⁰ and Raphaela Goldbach-Mansky ¹¹, ¹National Institutes of Health, Bethesda, ²Bordeaux Cedex, France, ³Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ⁴Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, ⁵Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁶NIAID, NIH, Bethesda, ⁷NIH/ NIAID, Rockville, ⁸NIH, ⁹NIH, NIAID, Bethesda, ¹⁰NIAID, NIH, Silver Spring, ¹¹NIH/NIAID, Potomac
Background/Purpose: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy And Elevated Temperature (CANDLE) Syndrome is an autoinflammatory interferonopathy caused by mutations in the genes encoding for components…
Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, Anne Eberhard ¹ and Joyce Hui-Yuen ², ¹Cohen Children's Medical Center, Lake Success, ²Cohen Children's Medical Center, New Hyde Park
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…
Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Uptej Khalsa¹ and Imelda Balboni ¹, ¹Stanford University, Palo Alto, California
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ⁷, Marinka Twilt ⁸ and Timothy Beukelman ⁹, ¹Florida, Gainesville, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵University of Alberta, Edmonton, Canada, ⁶Amgen, Long Beach, ⁷Amgen, Inc, San Francisco, ⁸Alberta Children's Hospital, Calgary, Canada, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 040 • 2020 Pediatric Rheumatology Symposium
Patient-Proxy Agreement on Mental Health and Neuropsychological Symptoms Among Youth with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ³, Nina Thomas ⁴, Kimberly S. Miller ⁴, Jami F. Young ⁴, Pamela Weiss ⁴, David D. Sherry ⁴ and Jeffrey S. Gerber ⁴, ¹Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ²Children's Hospital of Philadelphia, Cherry Hill, ³University of Pennsylvania, Philadelphia, ⁴Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Adolescents with juvenile fibromyalgia syndrome (JFMS) present with a myriad of mental health and neuropsychological symptoms, including dyscognition (“brain fog”); however, patient-proxy agreement on…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…

1
2
3
…
10
Next Page »